• Markets
  • icon
  • Companies
NEU · ASX

Neuren Pharmaceuticals Limited (ASX:NEU)

AU$21.09

 -0.71 (-3.257%)
ASX:Live
17/05/2024 04:10:34 PM
HALO Small HALO Price Momentum HALO Ords HALO MQV SMALL HALO MQV +7
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

NEU Overview

NEU Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Strong

MQV Small

Very Weak

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Weak

Growth

Earnings

Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About NEU

Telephone

Address

Description

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.

NEU Price Chart

Key Stats

Market Cap

AU$2.83B

PE

14.30

EV/EBITDA

11.3

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 10.02 - 25.95

Trade Value (12mth)

AU$2,243,586.00

1 week

10.65%

1 month

11.47%

YTD

-15.03%

1 year

47.28%

All time high

25.950000762939453

Key Fundamentals

EPS 3 yr Growth

-1498.100%

EBITDA Margin

86.30%

Operating Cashflow

$185m

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

500.40

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

130m

HALO Sector

Next Company Report Date

04-Mar-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

1.97

NEU Announcements

Latest Announcements

Date Announcements

16 May 24

Neuren CEO to present at BIO & Jefferies conferences in US

×

Neuren CEO to present at BIO & Jefferies conferences in US

15 May 24

Investor presentation, 15 May 2024

×

Investor presentation, 15 May 2024

09 May 24

DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m

×

DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m

07 May 24

Notification of cessation of securities - NEU

×

Notification of cessation of securities - NEU

26 April 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

26 April 24

Virtual AGM online guide

×

Virtual AGM online guide

26 April 24

Notification of cessation of securities - NEU

×

Notification of cessation of securities - NEU

24 April 24

Q1 2024 quarterly activity and cash flow report

×

Q1 2024 quarterly activity and cash flow report

23 April 24

2023 Annual Report to shareholders

×

2023 Annual Report to shareholders

23 April 24

Appendix 4G

×

Appendix 4G

23 April 24

Trofinetide accepted for Priority Review by Health Canada

×

Trofinetide accepted for Priority Review by Health Canada

08 April 24

Application for quotation of securities - NEU

×

Application for quotation of securities - NEU

12 March 24

Application for quotation of securities - NEU

×

Application for quotation of securities - NEU

29 February 24

Neuren 2023 results investor webinar on 29 February 2024

×

Neuren 2023 results investor webinar on 29 February 2024

29 February 24

Appendix 4E and 2023 full year accounts

×

Appendix 4E and 2023 full year accounts

29 February 24

Neuren reports profit of $157 million for 2023

×

Neuren reports profit of $157 million for 2023

29 February 24

2023 Results webinar

×

2023 Results webinar

28 February 24

DAYBUE net sales US$87.1 million in Q4 2023

×

DAYBUE net sales US$87.1 million in Q4 2023

16 February 24

Pause in Trading

×

Pause in Trading

16 February 24

Comment on research report

×

Comment on research report

08 February 24

Notification regarding unquoted securities - NEU

×

Notification regarding unquoted securities - NEU

01 February 24

Application for quotation of securities - NEU

×

Application for quotation of securities - NEU

31 January 24

Q4 2023 quarterly activity report

×

Q4 2023 quarterly activity report

31 January 24

Q4 2023 Appendix 4C Cash Flow Report

×

Q4 2023 Appendix 4C Cash Flow Report

20 December 23

Completion of enrolment in Neuren's Angelman P2 trial

×

Completion of enrolment in Neuren's Angelman P2 trial

NEU Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 0.00 1.20 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 0.00 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 22.9 102.3 79,966.7 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 1,826.7 14.3 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 334.9 11.3 Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 0.02 1.41 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.08 0.03 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.9 142.7 5,710.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.2 0.3 N/A Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.30 0.33 1.74 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.30 0.33 1.92 Lock Lock Lock
     Growth % Lock Lock Lock Lock 47.9 8.5 482.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 118 129 N/A Lock Lock Lock
Basic m Lock Lock Lock Lock 118 126 N/A Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 15 232 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A 1,493.7 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 16 N/A Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 15 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.3 181,887.5 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A 99.9 N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A 0 N/A Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -11 -2 200 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.0 86.1 12,719.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -10.9 86.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 3 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -11 -2 200 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.0 86.0 12,640.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A -11.0 86.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -11 -1 N/A Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -3 -1 N/A Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 0 162 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.2 102.4 88,193.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A 1.3 70.0 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -10 4 185 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -127 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 22 0 4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -10 4 186 Lock Lock Lock
     Growth % Lock Lock Lock Lock -23.5 135.9 5,106.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A 0.2 0.8 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 37 40 N/A Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 40 43 248 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 N/A Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -37 -40 -138 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 2 N/A Lock Lock Lock
Equity $m Lock Lock Lock Lock 39 42 205 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 39 42 N/A Lock Lock Lock
     Growth % Lock Lock Lock Lock 62.2 6.0 N/A Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -19.5 0.4 65.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -19.9 0.4 79.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -36.0 -3.9 N/A Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -24.6 0.5 N/A Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -31.4 8.9 N/A Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A 500.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 3.2 25.3 -0.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -93.7 -96.6 -67.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 49.9 25.8 N/A Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 49.9 25.8 N/A Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 91.9 92.9 N/A Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -1,241.6 214.5 431.3 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 11.6 N/A Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.4 N/A Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A 1.8 N/A Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.3 0.9 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.3 0.9 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A -4.7 N/A Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A -1.6 N/A Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -19.5 0.4 65.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -19.9 0.4 79.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 N/A Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -19.9 0.4 N/A Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A 31.5 N/A Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A 31.5 N/A Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 9,407.2 9,170.9 N/A Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -9,407.2 -9,139.3 N/A Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

1.97%

Value ($M)

48

Prior Change

N/A

7 Day Change

0.20%

1 Month Change

0.40%

3 Month Change

1.20%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NEU Shortsell

Frequently Asked Questions

The current share price of Neuren Pharmaceuticals Limited (NEU:ASX) is AU$21.09.
The 52-week high share price for Neuren Pharmaceuticals Limited (NEU:ASX) is AU$25.95.
The 52-week low share price for Neuren Pharmaceuticals Limited (NEU:ASX)? is AU$10.02.
The current TTM dividend payout for Neuren Pharmaceuticals Limited (NEU:ASX) is 0.00.
Neuren Pharmaceuticals Limited (NEU:ASX) does not pay a dividend.
Neuren Pharmaceuticals Limited (NEU:ASX) has a franking level of 0.0%.
Neuren Pharmaceuticals Limited (NEU:ASX) is classified in the Healthcare.
The current P/E ratio for Neuren Pharmaceuticals Limited (NEU:ASX) is 14.30.